Dr. Woyach on a Study Combining MOR208 With Lenalidomide for the Treatment of CLL

Jennifer Woyach, MD
Published: Wednesday, Dec 07, 2016

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study examining the use of MOR208 combined with lenalidomide (Revlimid) for the treatment of chronic lymphotic leukemia (CLL) during the American Society of Hematology (ASH) Annual Meeting.
The study includes 4 cohorts of patients – including patients with relapse/refractory CLL, treatment naïve CLL, richter’s transformation, and patients who have received treatment with ibrutinib (Imbruvica) and have developed mutations that will render them resistant to ibrutinib without having clinical progression, Woyach says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication